We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleMichael Kotsanis – CEO & Managing Director – Acrux Limited (ASX:ACR) is a speciality pharma co...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleASX 200 down on Tuesday; energy and iron ore stocks rise BHP’s profit up 2pc, but dividend cut. Lov...
Read ArticleAcrux’s stock jumped after the US FDA approved its acne gel This new product addresses a market wor...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleMomentum investing involves taking advantage of, and making profits from, upward trends in a stock....
Read ArticleThis week’s Bulls N’ Bears ASX Runner of the Week is… Regeneus Ltd. Its share price surged 220 per c...
Read ArticleSpecialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic...
Read ArticleAcrux Ltd (ASX: ACR) shares are avoiding the market weakness and rocketing higher on Wednesday. In...
Read ArticleStockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) pe...
Read ArticleMomentum trading involves taking advantage of, and making profits from, upward trends in a stock. It...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleAsk any chief of a development-stage biotech about the prospect of a partnering or licencing deal an...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleTim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis a...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleThe ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best...
Read ArticleS&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or...
Read ArticleAcrux (ACR) receives approval from the US FDA to review a generic version of its nitroglycerin ointm...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleBy Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticlePfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of...
Read ArticleThe Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleAcrux (ACR) reaches agreement for EUR 4.10 million (A$6.41 million) buyout of future Lenzetto royalt...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleAcrux (ACR) and its partner, Padagis, launch a prilocaine and lidocaine cream product in the United...
Read ArticleHighlights The ASX 200 benchmark index closed in the green today (21 December), gaining 90.80 po...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleASX 200 bounces back to grind out a 0.47% win for the day HitIQ’s new deals look set to cement its...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleBenchmark finishes up after fierce struggle for buoyancy Absolutely no one shocked to learn Star’s...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleQueen Elizabeth II soared off into the heavens Classic Minerals pulls off an amazing impersonation...
Read ArticleAcrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commen...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticlePharmaceutical company Acrux (ACR) enters an exclusive commercial agreement with US-based Padagis f...
Read ArticleAntisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor ge...
Read ArticleHighlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and pre...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleWhen it comes to analysing company results, interpretations can differ as widely as Russian news age...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleThe Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this t...
Read ArticleThe ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on...
Read ArticleShareCafeAustralia… One Hour In… ASX200 down 62 ASX200 down 62 points (0.9%) to 7257. Acrux (-3.8...
Read ArticleHighlights Qantas Airways shares dropped after the ACCC rejected its alliance with Japan Airline...
Read ArticleHighlights Australian benchmark index, the ASX 200, traded higher by 0.3% by mid session. Five...
Read ArticleWall Street falls again for fourth consecutive day All three major US stock market benchmarks fell o...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleThe ASX 200 health stocks index (XHJ) fell by 1.55% this morning, compared to the broader index whic...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSummary Openpay (ASX:OPY) delivers strong growth in Q4 FY21, marks 141% rise in active plans Ri...
Read ArticleSummary The ASX 200 traded lower by 24 points or 0.32% at 7,408 by the lunch. Six of 11 sectors...
Read ArticleASX 200 health stocks index rose by 0.21% this morning, compared to the broader index which fell by...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleOver the past month, a number of US FDA approvals have moved the share prices of global pharma stock...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSummary The ASX 200 closed 1.48% higher at 7,342.20, recouping previous session losses. Ten of...
Read ArticlePlenty of action on the biotech front today has provided ASX investors with some mouth-watering gain...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading d...
Read ArticleSummary The ECT share price has rocketed 50% to AU$0.002, clocking a volume of over 4 million sh...
Read ArticleAfter a tumultuous journey, biotech Acrux (ASX:ACR) will finally be able to sell its toenail fungus...
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 93 ASX200 up 93 points (1.3%) to 7328. Acrux (+35%); the...
Read ArticleThe Acrux Limited (ASX: ACR) share price has been an exceptionally strong performer on Tuesday. In...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleSummary The ASX 200 ended 10.70 points or 0.15% higher at 7292.60, setting a new 100-day high....
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 20 ASX200 up 20 points (0.3%) to 7302. Acrux (-7%); annou...
Read ArticleThe capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the fir...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read Article2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In th...
Read ArticleThe FDA has notified Acrux that its Abbreviated New Drug Application submission has been approved an...
Read ArticleSummary Drug development company Acrux Limited has got the green light from the US FDA for its g...
Read ArticleThe Acrux Limited (ASX: ACR) share price is soaring today, up 36.36% at the time of writing to 22 c...
Read ArticleWhen it comes to biotech stocks, the ultimate goal is always to get a drug to market. Acrux today sh...
Read ArticlePharmaceutical company Acrux (ASX: ACR) has secured United Stated Food and Drug Administration appro...
Read ArticleShareCafeAustralia…One Hour In…ASX up 10 points ASX200 up 10 points (0.1%) to 6707. Acrux (+48%); t...
Read ArticleJobkeeper subsidies will make up two thirds of dental group 1300 Smiles’ (ASX:ONT) final dividend at...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleBelieve it or not, there are a handful of shares that you can still buy today on the ASX that are e...
Read ArticleAnother day, another biotech winner. The Acrux Ltd [ASX:ACR] share price is up 33.33% at time of wri...
Read ArticleA quick wrap of the key winners and losers on Friday, May 29. Data is taken after the market closes...
Read ArticleThe Acrux Limited (ASX: ACR) share price has taken off this morning, bolting out of the gates to be...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleYou don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the...
Read ArticleThe 10th Annual Australian Microcap Investment Conference will be held on Tuesday 22 October 2019 ov...
Read ArticleFirstWave Cloud Technology (ASX: FCT) has won technology super-aggregator Digital WholeSale Solution...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
